Tag : FOLFIRI

BREAKWATER cohort 3 showed encorafenib + cetuximab (EC) + FOLFIRI significantly improved PFS and OS vs. control in first-line BRAF V600E-mutant metastatic colorectal cancer (mCRC). Featuring a manageable safety profile and consistent benefit across key prespecified subgroups, supporting its potential role as a new standard treatment alongside timely biomarker-driven, individualized care strategies.